In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Snack rats eat biobased fiber optic cables, send London’s G.Network into bankruptcy
In the United Kingdom, London internet provider G.Network has entered administration because it used fiber optic cable jackets made of soy- and corn-based materials...
Samsung creates e-paper with phytoplankton display
In South Korea, Samsung Electronics has unveiled an e-paper with a display made of phytoplankton-based plastics.
E‑paper is a display technology that replicates the...
Make Good launches mushroom-based shoes
In Australia, shoe brand Make Good has created a Derby shoe style with a variety of biobased materials. Dubbed Derby V1, the shoe includes...